Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
Sponsor: Peking Union Medical College Hospital
Summary
This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease. And evaluates the potential of Al18F-NOTA-FAPI PET imaging in Clinical treatment strategy guidance.
Key Details
Gender
All
Age Range
18 Years - 88 Years
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2022-05-10
Completion Date
2028-12-31
Last Updated
2026-02-10
Healthy Volunteers
Yes
Interventions
Al18F-NOTA-FAPI PET/CT(or PET/MRI)
Participants will receive an intravenous injection of Al18F-NOTA-FAPI, prepared on-site and measured by qualified personnel using a dose calibrator, with readings and time recorded. The radiopharmaceutical will be slowly administered through a three-way stopcock, followed by a flush with 5 mL of normal saline. The recommended dose is approximately 4.81 MBq/kg (0.13 mCi/kg) body weight, with variations depending on drug yield and clinical scheduling. PET/CT(or PET/MRI) imaging are planned 45-90 minutes after administration, with adjustments based on drug yield and equipment availability.
Locations (1)
Peking Union Medical College Hospital
Beijing, China